Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Picks Valproate For First Public Hearing On Safety Of Marketed Medicines

Executive Summary

The European Medicines Agency is re-examining the use of valproate in women to address ongoing safety concerns and will hold its first ever public hearing later this year to listen directly to the experience of EU patients with these medicines.


Related Content

EMA Urged To Do Better On Valproate Risk Reduction In Pregnant Women
Parties Vie For Place At EMA’s First Ever Public Hearing On Medicines Safety
French Study Confirms Teratogenic Risks Of Valproate; Other Drugs In The Spotlight Too
Waiting For The Perfect Case: Why EMA Has Yet To Hold A Public Drug Safety Hearing
EMA to go extra mile to facilitate joint safety study for valproate





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts